PAION has initiated a phase 3 clinical trial of Remimazolam, an ultra-short-acting anesthetic for use during colonoscopy, according to a News Medical report.
The phase 3 clinical trial is a prospective, double-blind, randomized, placebo and midazolam-controlled multicenter study, according to the report. During phase 2 clinical trials, Remimazolam was found to have a faster onset of sedation and faster patient recovery in comparison to midazolam.
The phase 3 clinical trial will include 460 patients undergoing diagnostic and therapeutic colonoscopy.